PERSONALIS INC (PSNL) Stock News

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Mentions: GH NTRA EXAS VCYT

What 5 Analyst Ratings Have To Say About Personalis

A Glimpse Into The Expert Outlook On Personalis Through 7 Analysts

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Mentions: TEM

Personalis to Participate at Upcoming Investor Conferences

Personalis Reports Third Quarter 2024 Financial Results

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis to Announce Third Quarter 2024 Financial Results

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Personalis to Participate at Upcoming Investor Conferences